Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Alnylam Sues Dicerna

    Here’s the latest RNAi dustup: Alnylam has filed a “trade secret misappropriation” lawsuit against Dicerna (thanks to a commenter here for mentioning this news). The real issue seems to be use of GalNAc conjugates for delivering siRNAs to the liver. Alnylam’s president, Barry Greene says that “Alnylam has led the disco… Read More
  • Business and Markets

    A Sudden Exit at AstraZeneca

    Hmm. FierceBiotech is reporting that AstraZeneca’s head of R&D, Briggs Morrison, has made a very sudden, very unexpected exit. People seem to have heard about this only this morning, and are being taken by surprise. . . Read More
  • Business and Markets

    Four Patients. Count ‘Em, Four.

    While we’re on the subject of market froth, take a look at what’s going on today. Sage Therapeutics announced the results of a study in post-partum depression. (Note – these are not the same people as Sage Bionetworks out in Seattle; this is a small company in Cambridge). They used SAGE-547, a GABA-A allosteric modulator… Read More
  • Alzheimer's Disease

    More on Axovant’s IPO

    Update: the IPO went off at the top of its range, I am sorry to report. More here from FierceBiotech, and I agree with John Carroll’s take. I wrote just recently about Axovant and their plans to go public with an Alzheimer’s therapy picked up on the cheap from GSK. Now here’s a look from… Read More
  • Business and Markets

    Bristol-Myers Squibb Sues a Former VP

    You don’t often see noncompete agreements invoked in the biopharma industry, but here’s one. According to Pharmalot, Bristol-Myers Squibb is suing a former executive (David Berman) for taking a job with AstraZeneca. Berman was highly placed in BMS’s immuno-oncology area, and this is such a competitive environment that they feel th… Read More
  • Business and Markets

    Two Types of Risk

    It’s the time for the ASCO meeting again, so everyone who follows oncology drug development will be busy catching up on the news. Bruce Booth has a good overview of things here, based on look at the abstracts submitted for the meeting. An analysis of the words mentioned in them shows some interesting features: the… Read More
  • Business and Markets

    Some Side Effect For An Antibody

    Remember back when AstraZeneca was fighting off Pfizer’s ardent, tax-issue-resolving embrace a year ago? One of their weapons was a pitch to their own shareholders about what potential their own pipeline had, and how much of that would presumably go to waste should the deal go through. Even at the time, people thought that their… Read More
  • Business and Markets

    Pfizer Rumors, Again

    Rumors continue to fly around that Pfizer is going to ease its merger hunger and its foreign-cash tax woes by making an offer for GlaxoSmithKline. Lord, what a mess that will be if it happens. Problem is, I can’t completely rule that out. I’m a very poor judge of huge pharma M&A deals, because most… Read More
  • Business and Markets

    Piling On Andrew Witty

    To go along with the recent calls for Andrew Witty to step down at GSK, here’s John LaMattina wondering if he’s the right guy for the job as well: . . .the bigger issue with Witty’s stance is the direction that he is taking GSK. His company has a long and proud history of delivering… Read More
  • Alzheimer's Disease

    An Alzheimer’s IPO, Because Why Not

    Now here’s someone with optimism to burn, compost, and scatter to the winds. According to FierceBiotech, Vivek Ramaswamy has started a company called Axovant Pharmaceuticals, and their asset is a 5-HT6 antagonist from GSK. It goes back to the SmithKline days, when it was known as SB742457. It was in development for Alzheimer’s, apparent… Read More
...181920...